Human Genome Sciences Initiates Phase 3 Clinical Trial Of Albuferon(R) In Combination With Ribavirin For Patients With Chronic Hepatitis C

Wed, 20 Dec 2006 02:00 PM EST

... Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has initiated dosing in ACHIEVE 1, one of two pivotal Phase 3 clinical trials of Albuferon(R) (albinterferon alpha 2b) in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. [click link for full article] ...